New drug combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT03946878
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This phase II trial is testing two oral drugs, venetoclax and acalabrutinib, in 32 people with mantle cell lymphoma that has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Both drugs work by blocking cancer cell survival and growth pathways.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax and acalabrutinib (two oral drugs)
- What this could lead to
- If this works, it could offer a new treatment option for people with mantle cell lymphoma that has come back or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase trial with only 32 participants. The drugs may not work for everyone, and side effects like low blood counts or infections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTOID VARIANT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Combination therapy aims to outsmart tough lymphoma
- New drug duo takes on tough lymphoma
- New combo attack on lymphoma shows promise in early trial
- Engineered immune cells target lymphoma after transplant
- New trial aims to bring targeted lymphoma drugs to minority patients